Aflibercept in wet AMD beyond the first year of treatment: recommendations by an expert roundtable panel by McKibbin, M. et al.
Volume 29 Supplement 1     July 2015
www.nature.com/eye
Aflibercept in wet AMD beyond the first year of treatment: 
recommendations by an expert roundtable panel
Eylea® ▼ (aflibercept solution for injection) Prescribing Information can be found at the end of the supplement.
L.GB.COM.05.2015.11280. Date of preparation: June 2015
eye_cover supplement.indd   1 18/06/2015   17:45
Aflibercept in wet AMD beyond the first year of
treatment: recommendations by an expert
roundtable panel
5 November 2014, London, UK
Description: Aflibercept was licensed in Europe for the treatment of wet AMD in November 2012. A national
roundtable was convened to discuss UK experience with aflibercept to date, and to use this experience, together
with expert opinion, to develop recommendations on the practical application of aflibercept in wet AMD after Year 1.
This paper summarises these recommendations.
Sponsorship: This supplement, and the meeting on which it is based, were sponsored by Bayer HealthCare. All authors
received honoraria, contributed to the development of the manuscript, and retained final control of the content and
editorial decisions. Medical writing assistance was funded by Bayer HealthCare and provided by AS&K
Communications Ltd. Bayer HealthCare checked that the content was factually accurate, balanced, and compliant
with the Association of the British Pharmaceutical Industry Code of Practice.
The views and opinions of the authors are not necessarily those of Bayer HealthCare or the publisher.
No part of this publication may be reproduced in any form without permission from the publisher.
Eyleas! (aflibercept solution for injection) Prescribing Information can be found at the end of the supplement.
July 2015 Volume 29, Supplement 1
OPEN
Aﬂibercept in wet AMD
beyond the ﬁrst year of
treatment: recommen-
dations by an expert
roundtable panel
M McKibbin1, H Devonport2, R Gale3, M Gavin4,
A Lotery5, S Mahmood6,7, PJ Patel8, A Ross9,
S Sivaprasad8, J Talks10 and G Walters11
Abstract
This paper provides expert recommendations on
administration of aﬂibercept in wet age-related
macular degeneration (AMD) after Year 1 (Y1),
based on a roundtable discussion held in
London, UK in November 2014. The goals of
treatment after Y1 are to maintain visual and
anatomical gains whilst minimising treatment
burden and using resources effectively. The
treatment decision should be made at the
seventh injection visit (assuming the label has
been followed) in Y1, and three approaches are
proposed: (a) eyes with active disease on
imaging/examination but with stable visual
acuity (VA) at the end of Y1 should continue
with ﬁxed 8-weekly dosing; (b) eyes with
inactive disease on imaging/examination and
stable VA should be managed using a ‘treat and
extend’ (T&E) regimen. T&E involves treating
and then extending the interval until the next
treatment, by 2-week intervals, to a maximum of
12 weeks, provided the disease remains inactive.
If there is new evidence of disease activity,
treatment is administered and the interval to the
next treatment shortened; and (c) if there has
been no disease activity for ≥ 3 consecutive
visits, a trial of monitoring without treatment
may be appropriate, initiated at the end of Y1 or
at any time during Y2. Where possible, VA
testing, OCT imaging and injection should be
performed at the same visit. The second eye
should be monitored to detect fellow eye
involvement. In bilateral disease, the re-
treatment interval should be driven by the
better-seeing eye or, if the VA is similar, the eye
with the more active disease.
Eye (2015) 29, S1–S11; doi:10.1038/eye.2015.77
Introduction
Neovascular or wet age-related macular
degeneration (AMD) accounts for 10–15% of all
cases of AMD.1 In the UK alone it was estimated
that there were 263 000 cases of wet AMD in
2007–2009, with an annual incidence of 39 700
new cases.2 The prevalence of wet AMD is
rising, and is expected to increase by one-third
by 2020.2 Without treatment, wet AMD leads
to severe central vision loss.
Wet AMD is typically characterised by the
growth of abnormal blood vessels from the
choroid into the space under the retinal pigment
epithelium or the neurosensory retina.3 These
new vessels can leak serous ﬂuid and/or blood,
leading to a reduction in central vision.3 Clinical
features of active wet AMD can include one or
more of the following: sub-retinal ﬂuid, intra-
retinal ﬂuid, sub-retinal haemorrhage, retinal
pigment epithelial detachment, and intra-retinal
exudates within the macula.4
Vascular endothelial growth factor (VEGF)
plays a key role in intraocular neovascularisation
in a number of conditions; it not only promotes
angiogenesis (by stimulating vascular
endothelial cell proliferation and migration) but
also increases vascular permeability.5 VEGF-A,
acting via the VEGF receptor 2, is thought
to be the main stimulator of angiogenesis and
vascular permeability in wet AMD.5
Anti-VEGF agents such as aﬂibercept
(EYLEA▼; aﬂibercept solution for injection,
Regeneron Pharmaceuticals, Inc, Tarrytown, NY
and Bayer HealthCare Pharmaceuticals, Berlin,
Germany) have become the mainstay of
treatment for wet AMD. Aﬂibercept is a fusion
protein, combining the key binding domains of
VEGF receptors 1 and 2 and the Fc portion of
immunoglobulin G. Dosing for aﬂibercept in wet
AMD is initiated with one 2mg injection per
month for three consecutive doses followed by
one 2mg injection every 2 months during the
ﬁrst year. Monitoring between injections is not
required. After 1 year of treatment, the treatment
interval may be extended based on visual and
anatomical outcomes (Table 1).6 In this event, the
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schedule of monitoring visits is determined by the
treating physician and may be more frequent than the
schedule of injections.
Aﬂibercept was licensed in Europe for the treatment of
wet AMD in November 2012, and approved by the
National Institute for Health and Care Excellence (NICE)
in July 2013. Given the 90-day commissioning rule,
all ophthalmology units in the UK would already be
expected (as of November 2014) to have some patients
who have completed 1 year of treatment with aﬂibercept.
A national roundtable was therefore convened to discuss
UK experience with aﬂibercept to date, and to use this
experience, together with expert opinion, to develop
recommendations on the practical application of
aﬂibercept in wet AMD after Year 1. In particular, the
discussion was based around maintaining the visual
acuity (VA) gains from Year 1 and reducing treatment
burden where possible. This paper will review the VEGF
Trap-Eye: Investigation of Efﬁcacy and Safety in Wet
AMD (VIEW) study with aﬂibercept in wet AMD,7,8 and
the recommendations developed by the panel.
Management of wet AMD in the UK
Guidance on the management of wet AMD in the UK has
been published by NICE9,10 and the Royal College of
Ophthalmologists (RCO).11 It should be noted that the
product label for ranibizumab has been changed since the
RCO guidance was published, and therefore these
guidelines are not presented below.
NICE technology appraisals on ranibizumab and
aﬂibercept in wet AMD
According to the NICE July 2013 technology appraisal
(TA294), aﬂibercept is recommended as an option for
treating wet AMD if it is used in accordance with the
NICE recommendations for ranibizumab and offered at
the discount agreed in the patient access scheme.9 The
criteria for ranibizumab use (based on the NICE
technology appraisal re-issued in May 2012; TA155) are
as follows: best-corrected visual acuity (BCVA) between
6/12 and 6/96; no permanent damage to the central
fovea; lesion size ≤ 12 disc areas in greatest linear
dimension; and evidence of disease progression.10
Treatment posology in the ﬁrst year of wet AMD therapy
For ranibizumab, the label states that treatment should be
given monthly until maximum VA is achieved and/or
there are no signs of disease activity. Monitoring and
treatment intervals can be extended thereafter.12 The
treatment interval should be extended by no more than
2 weeks at a time in wet AMD.12
As outlined above, aﬂibercept treatment (2 mg) is
initiated with one injection per month for 3 months.
Thereafter, treatment continues at 2-monthly injections for
the remainder of Year 1 (Table 1).6
Aﬂibercept in clinical trials
VIEW study design
VIEW 1 and 2 were two phase III, randomised, double-
blind, multicentre, head-to-head non-inferiority trials that
compared aﬂibercept with ranibizumab in patients aged
≥ 50 years with wet AMD.7,8 VIEW 1 was conducted at
154 centres (n= 1217) in the USA and Canada, while
VIEW 2 was conducted at 172 centres (n= 1240) in Europe
(including the UK), the Middle East, Asia-Paciﬁc and
Latin America.7
Patients were randomised 1:1:1:1 to aﬂibercept 2mg
every 4 weeks (2q4), aﬂibercept 2mg every 8 weeks (after
three initial doses; 2q8), aﬂibercept 0.5 mg every 4 weeks
(0.5q4) or ranibizumab 0.5mg every 4 weeks (Rq4).
Treatment continued to week 52.7 From weeks 52–96,
patients were monitored each month and were treated
either reactively or proactively in a ‘capped pro re nata
(PRN)’ protocol. ‘Reactive’ treatment was based on the
presence of disease activity (deﬁned as: new or persistent
ﬂuid on OCT; increase in central retinal thickness of
≥ 100 μm compared with lowest previous value;
loss of ≥ 5 Early Treatment Diabetic Retinopathy Study
(ETDRS) letters from best previous score in conjunction
with recurrent ﬂuid on OCT; new-onset classic
neovascularisation; new or persistent leakage on
ﬂuorescein angiography; or new macular haemorrhage).
Table 1 European posology of aﬂibercept in wet age-related macular degeneration6
K The recommended dose is 2mg aﬂibercept
▪ Equivalent to 50 μl
K Treatment is initiated with one injection per month for three consecutive doses, followed by one injection every 2 months
▪ No requirement for monitoring between injections
K After the ﬁrst 12 months of treatment, the treatment interval may be extended on the basis of visual and anatomical outcomes
▪ In this case the schedule for monitoring should be determined by the treating physician and may be more frequent than the
schedule of injections
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‘Proactive’ treatment meant treating irrespective of
disease activity. In VIEW, proactive treatment occurred
if 12 weeks had elapsed since the last injection. Reactive
treatment has been shown to result in worse VA
outcomes than continuous therapy,13,14 suggesting
under-treatment in some patients, whilst it is generally
accepted that proactive regimens can result in
over-treatment in a proportion of patients.
VIEW study results
Aﬂibercept results are shown for the 2q8 (licensed
posology) arm only. Aﬂibercept was non-inferior (10%
margin) to ranibizumab with respect to the primary
endpoint, that is the proportion of patients maintaining
vision (deﬁned as losing o15 ETDRS letters) at week 52
(95.3% for aﬂibercept; 94.4% for Rq4). These proportions
remained largely similar at week 96 (92.4 and 91.6%,
respectively).8
Mean BCVA increased and was sustained over
52 weeks with both aﬂibercept and ranibizumab. BCVA
gains from baseline to weeks 52 and 96 were similar
between aﬂibercept and ranibizumab (Figure 1). In
general, aﬂibercept was similar to ranibizumab at weeks
52 and 96 for all other secondary efﬁcacy endpoints
examined, including the proportion of patients gaining
≥ 15 ETDRS letters, anatomical outcomes (change in
choroidal neovascularisation [CNV] area, change in
central retinal thickness [exploratory endpoint; Figure 2]
and the proportion of eyes with a dry retina [post-hoc
endpoint]) and change in National Eye Institute Visual
Function Questionnaire-25 score.7,8
Between weeks 52 and 96, the mean number of
injections was 4.2 (standard deviation [SD], 1.7) and 4.7
(SD, 2.2) in the aﬂibercept and Rq4 groups, respectively.
Overall, 15.9% of patients receiving aﬂibercept required
frequent treatment (deﬁned here as ≥ 6 injections between
weeks 52 and 96) and 84.1% required less frequent
treatment (o6 injections between weeks 52 and 96).8
Forty-eight per cent of patients in the aﬂibercept arm had
three or fewer injections (ie the minimum number of
injections, or fewer due to missed injections) between
weeks 52 and 96.15
Both aﬂibercept and ranibizumab demonstrated a
favourable safety proﬁle. Serious ocular adverse events
were infrequent, occurring in 3.9% of aﬂibercept-treated
patients and 4.4% of ranibizumab-treated patients over
the 96-week treatment period. Serious systemic adverse
events were typical of those seen in an elderly population
receiving intravitreal treatment for wet AMD. The
incidence of Antiplatelet Trialists’ Collaboration events
was similar between aﬂibercept and ranibizumab.8
National roundtable meeting
The roundtable meeting was sponsored by Bayer
HealthCare. The expert panel was made up of 10 medical
retina specialists and took place in London, UK on
5 November 2014. In advance of the meeting each
participant was sent a questionnaire that was used to
gather information about the number of wet AMD
patients treated at their unit, the treatment distribution
in their practice and the aﬂibercept treatment approach
employed at each stage of management (up to 3 months,
3–11 months and 11 months onwards). Participants were
also asked to provide audit data on the use of aﬂibercept
in Year 1 at their institution, and to present these to the
rest of the panel at the meeting. The questionnaire and
audit data were used as the basis for the discussion of
aﬂibercept use post-Year 1.
Figure 1 VIEW: mean change in best-corrected visual acuity
(BCVA) from baseline to week 96.8 Reprinted from Ophthalmol-
ogy, 121(1). Schmidt-Erfurth U, Kaiser PK, Korobelnik J-F, Brown
DM, Chong V, Nguyen QD, et al. Intravitreal aﬂibercept injection
for neovascular age-related macular degeneration: ninety-six-
week results of the VIEW studies. p193–201 (2014), with
permission from Elsevier. LS, least squares; q4, every 4 weeks;
q8, every 8 weeks; R, ranibizumab.
Figure 2 VIEW: change to central retinal thickness from
baseline to 96 weeks.8 Reprinted from Ophthalmology, 121(1).
Schmidt-Erfurth U, Kaiser PK, Korobelnik J-F, Brown DM, Chong
V, Nguyen QD, et al. Intravitreal aﬂibercept injection for
neovascular age-related macular degeneration: ninety-six-week
results of the VIEW studies. p193–201 (2014), with permission
from Elsevier. q4, every 4 weeks; q8, every 8 weeks; R,
ranibizumab.
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A summary of the recommendations generated by the
expert panel is presented below.
Recommendations for aﬂibercept after Year 1
It should be noted that, when referring to the label, the
authors refer to month- rather than week-based dosing in
this paper to reﬂect the licensed posology for aﬂibercept
(stated in months). However, as most clinics are set up
using weekly rather than monthly schedules, practice
recommendations are given using week- rather than
month-based dosing. As an example, ‘8-weekly’ dosing
is considered to be equivalent to ‘2-monthly’ dosing.
The dosing schedule for aﬂibercept in Year 1 is shown
in Figure 3.
Goals of treatment after Year 1
The goals of wet AMD treatment after Year 1 are to
maintain visual and anatomical gains. These goals should
be achieved by: individualising treatment regimens;
minimising the treatment burden; and using resources
cost-effectively. In the UK, this means delivering
treatment within the local service framework and the
NICE commissioning guidance. The recommendations
presented here take into consideration the fact that clinic
capacity limitations may have a bearing on treatment
decisions; suggestions are provided for clinics where
capacity is not an issue, and alternatives for clinics
where capacity might be a limitation.
Treatment approaches after Year 1
As yet, there is no way to predict the amount of treatment
needed with either aﬂibercept or other anti-VEGF
therapies for an individual. This is reﬂected in the large
range of injection frequencies found in trials. For example,
in the discontinuous arm of the Inhibition of VEGF in
Age-related Choroidal Neovascularisation (IVAN) study,
the 25% of eyes with the lowest injection frequency
required o8 injections in total to the end of Year 2,
and the 25% of eyes with the highest injection frequency
required 417 injections in total (after three initial
doses).14 Similar ﬁndings were observed in the
Comparison of Age-related Macular Degeneration
Treatments Trials (CATT). In Year 1, the mean number of
injections for eyes receiving PRN treatment throughout
Year 1 and Year 2 was 6.9 (SD: 3.0) for ranibizumab and
7.7 (SD: 3.5) for bevacizumab.16 The mean number of
injections to the end of Year 2 was 12.6 (SD: 6.6) and
14.1 (SD: 7.0), respectively.13 This corresponds to
approximately 5.7 injections in the ranibizumab arm and
6.4 injections in the bevacizumab arm in Year 2; the
large SDs suggesting that many eyes required very little
treatment. Likewise, in eyes switched to PRN treatment
in Year 2, the mean number of injections was 5.0 for
ranibizumab and 5.8 for bevacizumab in Year 2, but the
SD values were again very wide (3.8 and 4.4,
respectively).13
Recommendations for the use of aﬂibercept in wet
AMD after Year 1 are presented below and in Table 2 and
Figure 4. It should be noted that the expert panel did not
feel that the VIEW study protocol for Year 2 (monthly
monitoring with a combination of reactive and proactive
therapy ie capped PRN) was a feasible option for many
Figure 3 Dosing schedule for aﬂibercept in Year 1. *Indicates
when the treatment approach for post-Year 1 is determined ie at
the time of the seventh injection in Year 1.
Figure 4 Algorithm for the treatment of wet age-related
macular degeneration with aﬂibercept after Year 1. aIn the
opinion of the treating physician. T&E, treat and extend; VA,
visual acuity.
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National Health Service (NHS) clinics owing to capacity
constraints and patient expectation, and the VIEW study
results suggest that this level of monitoring is not likely
to be necessary for many patients.8,15 This approach is
therefore not suggested in the panel’s recommendations.
Three different treatment approaches are recommended
for post-Year 1: (a) continuing with a ﬁxed 8-weekly
dosing regimen; (b) an individualised T&E regimen; and
(c) a trial of monitoring without treatment and with
extended follow-up intervals. The decision on the
treatment approach after Year 1 should be made at the
seventh injection in Year 1, based on the presence of active
or inactive disease and taking into account the best VA
and retinal anatomy achieved during the whole of Year 1.
Whichever treatment approach is selected, OCT imaging
should be performed and VA should be recorded
at every visit post-Year 1 if possible; this should be
undertaken in both eyes in order to detect fellow eye
involvement early.
Approach A: Fixed 8-weekly dosing
Treatment strategy
This strategy involves continuing with proactive, ﬁxed
8-weekly dosing. At the seventh injection visit in Year 1,
the patient is re-injected and the next injection is
scheduled for 8 weeks’ time. OCT imaging and VA
assessment are conducted at each visit if possible.
Monitoring is not required between injections.
Table 2 Summary of recommendations for aﬂibercept in wet age-related macular degeneration with aﬂibercept after Year 1
Treatment goals
K The goals of treatment after Year 1 are to maintain the visual and anatomical gains
K These goals should be achieved while minimising the treatment burden and using resources cost-effectively
Patient groups and their treatment approachesa
K Approach 1: Eyes with active diseaseb but stable VAc at the end of Year 1 should continue with ﬁxed 8-weekly dosing
▪ The patient is injected and the next injection is scheduled for 8 weeks’ time
K Approach 2: Eyes with inactive diseaseb and stable VAc are eligible for individualised T&E
▪ The patient is injected and the interval to the next injection is extended, by 2-week intervals, up to a maximum of 12 weeks
▪ In eyes that develop active diseaseb during T&E, the patient is injected and the interval to the next injection is reduced by 2-weekly
intervals
K Approach 3: Eyes that have had inactive diseaseb and stable VAc for at least three consecutive visits may be considered for a trial of
monitoring without treatment and with extended follow-up intervals
▪ This could be initiated at the end of Year 1 or during Year 2
▪ The patient undergoes monitoring and the interval to the next monitoring visit may be extended, by 2-week intervals, up to a
maximum of 12 weeks
Discharge strategy
K Patients who may be suitable for discharge should be seen by an ophthalmologist in person to allow for a full-informed discussion
K As an alternative to discharge, patients can be followed up at regular intervals in a community setting to check for changes in visual
function in either eye
▪ If active disease develops during this time, the patient should return to the clinic for treatment
Fellow eye involvement
K Both eyes should be monitored using OCT, to ensure that fellow eye involvement is captured early
K If a patient is having bilateral therapy, treatment intervals should be tailored to patient visits in order to synchronise treatment of
both eyes
K The better-seeing eye should drive the re-treatment interval for the worse-seeing eye. If the VA is similar between eyes (difference in
VA between eyes ≤ 5 letters), the eye with the most active disease should drive the re-treatment interval
Safety
K The risk–beneﬁt proﬁle should be discussed with the patient before initiating therapy and each time the treatment regimen is altered
Comorbidities
K Comorbidities that affect a patient’s ability to get to the clinic may inﬂuence the treatment approach
K An informed discussion with the patient is vital
Abbreviations: AMD, age-related macular degeneration; OCT, optical coherence tomography; T&E, treat and extend; VA, visual acuity.
aMonitoring (OCT and VA examination) should be performed at every visit.
bIn the opinion of the treating physician.
cVA should relate to the best VA achieved during the ﬁrst year of treatment.
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Eyes suitable for ﬁxed dosing
Eyes with active disease (in the opinion of the treating
physician) but stable VA at the end of Year 1 should
continue with ﬁxed 8-weekly dosing after Year 1. The
rationale for ﬁxed dosing at this stage is, therefore, to
continue regular treatment throughout the second year of
treatment in eyes with persistent disease activity at the
end of Year 1.
Treatment burden and ﬁxed dosing: progress to T&E after
Year 2
Fixed dosing should continue throughout the second year
of treatment. Thereafter, individualised T&E (see below)
may be considered in order to minimise treatment burden
and to maximise resource utilisation.
Approach B: Individualised T&E
Treatment strategy
The goal of T&E (an example of a proactive treatment
regimen) is to ﬁnd the optimal treatment interval at which
patients can achieve maximum control of disease activity
and stabilisation of VA with minimum treatment burden.
T&E begins with an extension of the treatment interval
after the seventh injection in Year 1. Treatment should
be extended by 2-week intervals, up to a maximum of
12 weeks. The goal should be to maintain a ‘stable’
outcome, deﬁned by the treating physician in consultation
with each patient and based on OCT imaging and VA
examination. Both imaging and examination should be
carried out at every visit if possible. Monitoring is not
required between injections.
As an example, at the seventh injection visit in Year 1,
the patient (who has completed an 8-weekly treatment
interval) is reviewed and re-injected. If there is no
evidence of disease activity on OCT imaging and
examination (in the opinion of the treating physician) and
the patient has stable VA, the treatment interval is
extended by 2 weeks and the next injection is scheduled
for 10 weeks’ time. At this time, VA is measured, an OCT
scan is performed and the patient is re-injected. If the
patient has stable disease (in the opinion of the treating
physician), the treatment interval is extended by a further
2 weeks, and the next injection is scheduled for 12 weeks’
time. Once the patient has achieved a 12-week treatment
interval, treatment should continue at this frequency
throughout the second year of treatment.
The T&E regimen also allows the physician to shorten
the treatment interval if there is new evidence of disease
activity (in the opinion of the treating physician) and/or
a reduction in VA. In these cases, OCT imaging is
performed, VA is assessed and the patient is injected.
The interval to the next treatment is shortened as
appropriate. For eyes with a small increase in disease
activity (e.g. those with some ﬂuid upon OCT but stable
VA), shortening the treatment interval by 2 weeks is
recommended. Eyes with signiﬁcant disease recurrence
(e.g. those with new CNV activity, a symptomatic
reduction in VA, extensive sub-retinal haemorrhage
or a marked change upon OCT) should undergo more
frequent monitoring, with treatment where necessary.
Eyes suitable for T&E
At the end of Year 1, eyes with inactive disease (in the
opinion of the treating physician) and stable VA are
eligible for individualised T&E. The rationale for T&E,
therefore, is to reduce the treatment burden and avoid
unnecessary treatment in patients who have successfully
achieved inactive disease at the end of Year 1.
Treatment burden and T&E: use of virtual clinics
The T&E regimen is suitable for both a one-stop service
(where OCT/VA and injection are performed on the
same day) and a two-stop service (where OCT/VA and
injection are performed on different days). In two-stop
clinics, the use of ‘virtual clinics’ can be employed to
reﬁne the patient pathway and improve capacity. Firstly,
the injection visit is scheduled based on the OCT imaging
and VA assessment from the previous visit. At the
injection visit, OCT imaging is performed and VA is
recorded prior to the injection. The OCT assessment then
takes place either at the time the patient visits, or remotely
(ie in the virtual clinic) at a later date by the consultant
ophthalmologist or by a non-medical member of staff
under supervision. The outcome of the OCT assessment
determines when the patient is asked to come back for
their next injection.
Approach C: Trial of monitoring without treatment
Treatment strategy
A trial of monitoring without treatment involves
performing OCT imaging and VA assessment without
giving an injection. The next planned monitoring visit
should take place after an interval of between 4 and
8 weeks initially, increasing by 2-week increments,
up to a maximum of 12 weeks.
If active disease (in the opinion of the treating
physician) develops during a trial of monitoring without
treatment, the patient should go back to T&E, starting at
8 weeks and extending out to 10 and 12 weeks, once
stable disease is achieved once more.
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Eyes suitable for a trial of monitoring without treatment
At the end of Year 1 or at any time-point during Year 2,
eyes that have had inactive disease and stable VA for at
least three consecutive visits (including the current visit)
may be considered for a trial of monitoring without
treatment. A trial of monitoring without treatment avoids
unnecessary treatment in patients who no longer require
treatment, eliminating the treatment burden altogether.
The observation that almost half of all patients in the
2q8 arm of VIEW had three or fewer injections between
weeks 52 and 9615 and data from the discontinuous
treatment arms of IVAN and CATT13,16 reinforces the
fact that a trial of monitoring without treatment may
be suitable for a substantial proportion of eyes. It is
unknown whether the 12-weekly injections in VIEW Year
2 were proactive (ie protocol-mandated injections because
12 weeks had elapsed since the last injection), reactive (ie
injection prompted by the presence of active disease) or a
combination or proactive and reactive. As a result, it is
unknown exactly how little or how much treatment these
patients really needed.
Treatment burden and a trial of monitoring without
treatment: use of virtual clinics
Where necessary, a trial of monitoring without treatment
can be conducted purely in the ‘virtual clinic’ to improve
capacity. As outlined above, OCT imaging and VA
assessments can be conducted in the virtual clinic,
while the OCT interpretation can be done online by the
consultant or by non-medical staff, under supervision.
Re-intensiﬁcation of treatment
The panel discussed the options for eyes showing a
greater treatment response during the initial monthly
treatment phase than during the 2-monthly treatment
phase. The interval between two doses of aﬂibercept
should not normally be shorter than 8 weeks, however the
RCO guidelines for wet AMD advise that hyperactive
lesions may for a short time require more intensive
therapy, at the discretion of the treating physician.11
Eyes with signiﬁcant disease reactivation during
treatment in Year 2 (for example those with a signiﬁcant
increase in ﬂuid and a symptomatic drop in VA) or
eyes with late disease recurrence after completing initial
aﬂibercept treatment should receive more frequent
monitoring, with treatment as necessary.
Given the complexity behind deﬁning late disease
recurrence after stopping treatment, however, further
recommendations on managing late disease recurrence
are beyond the scope of this article.
Discharge strategy
Given that aﬂibercept has only been licensed in the UK for
2 years, very few patients have been discharged to date.
As a result, the proposed discharge strategy is based on
experience with only a small number of patients.
Patients with stable VA who have not received any
treatment for a period of 12 months or more may be
considered for discharge from an active treatment service
either into virtual or community clinics, or without planned
further review. These patients should be seen by an
ophthalmologist in person to allow for a fully informed
discussion. Discharge by letter, without any direct patient
contact, under these circumstances is discouraged. One
should bear in mind that, in most cases, discharge will only
be an option beyond the second year of treatment, that is,
beyond the scope of our recommendations.
Data from the SEVEN-UP study suggest that wet AMD
is a chronic disease requiring chronic treatment.17
Consequently, patients with wet AMD may re-present
some time after their last injection. Follow-up at regular
intervals (at least once a year), for example with a
community optometrist or in virtual clinics, can be
considered as alternatives to discharge, in order to check
for changes in visual function in either eye. If late disease
recurrence develops during this time, the patient should
return to the clinic for treatment. Treatment should not be
re-initiated if the patient no longer meets the criteria
outlined in the NICE TA for ranibizumab.10
Fellow eye involvement
Once a patient has been diagnosed as having wet AMD in
one eye, the risk of CNV in the fellow eye is high; in a
study in patients with extrafoveal CNV, the 5-year
incidence of CNV was reported to be 26%.18 Thus, it is
important to monitor both eyes using OCT, to ensure that
fellow eye involvement is detected early. There is
increasing evidence to suggest that starting treatment
with vision better than 6/12 maintains good vision,19
however it should be noted that this is outside of NICE
guidance and may require an individualised funding
request to local commissioners.
If a patient is having bilateral therapy, treatment
intervals should be tailored to patient visits in order to
synchronise treatment of both eyes. The better-seeing eye
should drive the re-treatment interval for the worse-
seeing eye. However, if visual function is similar in the
two eyes (difference in VA between eyes ≤ 5 letters),
then the eye with more active disease should drive the
re-treatment interval. Patients should receive the same
anti-VEGF therapy in both eyes.
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Other considerations
In terms of safety considerations, the risk–beneﬁt proﬁle
should be discussed with the patient before initiating
treatment and each time the treatment regimen is
altered. It should be highlighted to the patient that
there is a small, added risk of ocular adverse events
associated with treatment, mostly related to the
injection procedure.
An informed discussion with the patient is necessary to
determine their treatment priorities or preferences. For
example, some patients may be more willing to accept
more frequent injections in order to try to achieve
additional improvements in vision. Such a patient might
be one who is keen to retain adequate visual acuity to
continue driving. On the other hand, some patients may
be unwilling to have very frequent injections and may
be willing to accept some degree of disease activity.
Examples include patients who have concerns about
the risks associated with treatment, those who have
experienced pain or an adverse event during or
after injection, or those who have difﬁculty with regularly
attending the clinic. The beneﬁt to treatment burden
may also vary according to whether the ﬁrst or second
eye is being treated.
Revised re-treatment criteria
Recommended re-treatment criteria were developed by
the panel at the roundtable meeting. The criteria were
based on those used in Year 2 of the VIEW study, updated
to reﬂect clinical experience. The deﬁnition of a ‘dry’ or
‘wet’ retina is highly variable between physicians, and
therefore the revised criteria suggest that patients are
re-treated when the treating physician considers there to
be disease activity.
The recommended re-treatment criteria are as follows:
Patients should be re-treated if, in the opinion of the treating
physician, there is new or persistent disease activity, as
indicated by one or more of the following (this list provides
examples but is not exhaustive):
K New or persistent ﬂuid as indicated by OCT, or
increase in central retinal thickness compared with the
lowest previous value as measured by OCT, or
K Loss of vision from the best previous VA if, in the
opinion of the treating physician, this is because of
disease activity, or
K New choroidal neovascularisation or new or persistent
leakage on ﬂuorescein angiography, or
K New macular haemorrhage
Conclusions
It is generally accepted that the VIEW study Year 2
protocol of monthly monitoring with capped PRN
treatment is not feasible for many NHS ophthalmology
clinics because of capacity constraints and patient
expectation, and is not mandated by the aﬂibercept label.
The recommendations given here offer alternative
treatment pathways after Year 1; the intention is to
maintain visual and anatomical gains whilst minimising
the treatment burden and using resources cost-effectively.
Three main treatment approaches are suggested:
(a) continuing with a ﬁxed 8-weekly dosing regimen for
eyes with active disease and stable VA at the end of
Year 1; (b) an individualised T&E regimen for eyes with
inactive disease and stable VA at the end of Year 1; and
(c) a trial of monitoring without treatment for eyes with
inactive disease and stable VA for three or more
consecutive visits either at the end of Year 1 or at any
point in Year 2.
The rationale for ﬁxed dosing at this stage is to continue
regular treatment in eyes with persistent disease activity
at the end of Year 1. Individualised T&E and a trial of
monitoring without treatment, on the other hand, help
to reduce the treatment burden and avoid unnecessary
treatment in patients who have successfully achieved
inactive disease by the end of Year 1. The use of virtual
clinics, where the consultant ophthalmologist or a non-
medical member of staff reviews OCT images remotely,
can be a means of improving clinic capacity during T&E
or a trial of monitoring without treatment.
Whichever treatment approach is selected, an informed
discussion with the patient is necessary to determine their
treatment priorities and their preferences regarding
disease control and treatment frequency, bearing in mind
the VA gains and the response to therapy during the ﬁrst
year of treatment.
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Prescribing Information
▼Eylea 40mg/ml solution for injection in a vial
(aﬂibercept) Prescribing Information
(Refer to full Summary of Product Characteristics
(SmPC) before prescribing)
Presentation: 1ml solution for injection contains 40mg
aﬂibercept. Each vial contains 100 microlitres, equivalent
to 4mg aﬂibercept. Indication(s): Treatment of
neovascular (wet) age-related macular degeneration
(AMD), macular oedema secondary to retinal vein
occlusion (branch RVO or central RVO) and visual
impairment due to diabetic macular oedema (DMO) in
adults. Posology & method of administration: For
intravitreal injection only. Must be administered
according to medical standards and applicable guidelines
by a qualiﬁed physician experienced in administering
intravitreal injections. Each vial should only be used for
the treatment of a single eye. The vial contains more than
the recommended dose of 2 mg. The extractable volume
of the vial (100 microlitres) is not to be used in total.
The excess volume should be expelled before injecting.
Refer to SmPC for full details. Adults: The recommended
dose is 2 mg aﬂibercept, equivalent to 50 microlitres.
For wAMD treatment is initiated with one injection per
month for three consecutive doses, followed by one
injection every two months. No requirement for
monitoring between injections. After the ﬁrst 12 months
of treatment, treatment interval may be extended based
on visual and/or anatomic outcomes. In this case the
schedule for monitoring may be more frequent than the
schedule of injections. For RVO (branch RVO or central
RVO), after the initial injection, treatment is given
monthly at intervals not shorter than one month.
Discontinue if visual and anatomic outcomes indicate that
the patient is not beneﬁting from continued treatment.
Treat monthly until maximum visual acuity and/or no
signs of disease activity. Three or more consecutive,
monthly injections may be needed. Treatment may
then be continued with a treat and extend regimen with
gradually increased treatment intervals to maintain stable
visual and/or anatomic outcomes, however there are
insufﬁcient data to conclude on the length of these
intervals. Shorten treatment intervals if visual and/or
anatomic outcomes deteriorate. The monitoring and
treatment schedule should be determined by the treating
physician based on the individual patient’s response.
For DMO, initiate treatment with one injection/month for
5 consecutive doses, followed by one injection every two
months. No requirement for monitoring between
injections. After the ﬁrst 12 months of treatment, the
treatment interval may be extended based on visual and/
or anatomic outcomes. The schedule for monitoring
should be determined by the treating physician. If visual
and anatomic outcomes indicate that the patient is not
beneﬁting from continued treatment, treatment should be
discontinued. Hepatic and/or renal impairment: No
speciﬁc studies have been conducted. Available data do
not suggest a need for a dose adjustment. Elderly
population: No special considerations are needed.
Limited experience in those with DMO over 75 years old.
Paediatric population: No data available. Contra-
indications: Hypersensitivity to active substance or any
excipient; active or suspected ocular or periocular
infection; active severe intraocular inﬂammation.
Warnings & precautions: As with other intravitreal
therapies endophthalmitis has been reported. Aseptic
injection technique essential. Patients should be
monitored during the week following the injection to
permit early treatment if an infection occurs. Patients
must report any symptoms of endophthalmitis without
delay. Increases in intraocular pressure have been seen
within 60min of intravitreal injection; special precaution
is needed in patients with poorly controlled glaucoma
(do not inject while the intraocular pressure
is≥ 30mmHg). Immediately after injection, monitor
intraocular pressure and perfusion of optic nerve head
and manage appropriately. There is a potential for
immunogenicity as with other therapeutic proteins;
patients should report any signs or symptoms of
intraocular inﬂammation e.g pain, photophobia or
redness, which may be a clinical sign of hypersensitivity.
Systemic adverse events including non-ocular
haemorrhages and arterial thromboembolic events have
been reported following intravitreal injection of VEGF
inhibitors. Safety and efﬁcacy of concurrent use in both
eyes have not been systemically studied. No data is
available on concomitant use of Eylea with other anti-
VEGF medicinal products (systemic or ocular). Caution in
patients with risk factors for development of retinal
pigment epithelial tears including large and/or high
pigment epithelial retinal detachment. Withhold
treatment in patients with: rhegmatogenous retinal
detachment or stage 3 or 4 macular holes; with retinal
break and do not resume treatment until the break is
adequately repaired. Withhold treatment and do not
resume before next scheduled treatment if there is:
decrease in best-corrected visual acuity of ≥ 30 letters
compared with the last assessment; central foveal
subretinal haemorrhage, or haemorrhage ≥ 50%, of total
lesion area. Do not treat in the 28 days prior to or
following performed or planned intraocular surgery.
Eylea should not be used in pregnancy unless the
potential beneﬁt outweighs the potential risk to the
foetus. Women of childbearing potential have to use
effective contraception during treatment and for at least
3 months after the last intravitreal injection. Populations
with limited data: There is limited experience of treatment
Treating wet AMD with aﬂibercept after Year 1: expert panel recommendations
M McKibbin et al
S10
This supplement has been sponsored by Bayer HealthCare. See page S9 for full disclaimer.
with Eylea in patients with ischaemic, chronic RVO.
In patients presenting with clinical signs of irreversible
ischaemic visual function loss, aﬂibercept treatment is not
recommended. There is limited experience in DMO due to
type I diabetes or in diabetic patients with an HbA1c over
12% or with proliferative diabetic retinopathy. Eylea
has not been studied in patients with active systemic
infections, concurrent eye conditions such as retinal
detachment or macular hole, or in diabetic patients with
uncontrolled hypertension. This lack of information
should be considered when treating such patients.
Interactions: No available data. Fertility, pregnancy &
lactation: Not recommended during pregnancy unless
potential beneﬁt outweighs potential risk to the foetus.
No data available in pregnant women. Studies in animals
have shown embryo-foetal toxicity. Women of
childbearing potential have to use effective contraception
during treatment and for at least 3 months after the last
injection. Not recommended during breastfeeding.
Excretion in human milk: unknown. Male and female
fertility impairment seen in animal studies with high
systemic exposure not expected after ocular
administration with very low systemic exposure. Effects
on ability to drive and use machines: Possible temporary
visual disturbances. Patients should not drive or use
machines if vision inadequate. Undesirable effects: Very
common: conjunctival haemorrhage (phase III studies:
increased incidence in patients receiving anti-thrombotic
agents), visual acuity reduced. Common: retinal pigment
epithelial tear, detachment of the retinal pigment
epithelium, retinal degeneration, vitreous haemorrhage,
cataract (nuclear or subcapsular), corneal abrasion or
erosion, corneal oedema, increased intraocular pressure,
blurred vision, vitreous ﬂoaters, vitreous detachment,
injection site pain, eye pain, foreign body sensation in
eyes, increased lacrimation, eyelid oedema, injection site
haemorrhage, punctate keratitis, conjunctival or ocular
hyperaemia. Uncommon: Injection site irritation, abnormal
sensation in eye, eyelid irritation. Serious: cf. CI/W&P—in
addition: blindness, endophthalmitis, cataract traumatic,
transient increased intraocular pressure, vitreous
detachment, retinal detachment or tear, hypersensitivity
(incl. allergic reactions), vitreous haemorrhage, cortical
cataract, lenticular opacities, corneal epithelium defect/
erosion, vitritis, uveitis, iritis, iridocyclitis, anterior
chamber ﬂare. Consult the SmPC in relation to other side
effects. Overdose: Monitor intraocular pressure and treat
if required. Incompatibilities: Do not mix with other
medicinal products. Special Precautions for Storage:
Store in a refrigerator (2 to 8 °C). Do not freeze. Unopened
vials may be kept at room temperature (below 25 °C) for
up to 24 h before use. Legal Category: POM. Package
Quantities & Basic NHS Costs: Single vial pack £816.00.
MA Number(s): EU/1/12/797/002. Further information
available from: Bayer plc, Bayer House, Strawberry
Hill, Newbury, Berkshire RG14 1JA, United Kingdom.
Telephone: 01635 563000. Date of preparation:
March 2015.
Eylea is a trademark of the Bayer Group.
Adverse events should be reported. Reporting forms and
information can be found at www.mhra.gov.uk/
yellowcard. Adverse events should also be reported to
Bayer plc. Tel.: 01635 563500, Fax.: 01635 563703,
E-mail: pvuk@bayer.com
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